Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice.
Antiviral Res
; 120: 85-8, 2015 Aug.
Article
en En
| MEDLINE
| ID: mdl-26026666
ABSTRACT
Long-acting nanoformulated antiretroviral therapy (nanoART) can sustain plasma drug levels and improve its biodistribution. Cell targeted-nanoART can achieve this and bring drug efficiently to viral reservoirs. However, whether such improvements affect antiretroviral responses remains unknown. To these ends, we tested folic acid (FA)-linked poloxamer407-coated ritonavir-boosted atazanavir (FA-nanoATV/r) nanoparticles for their ability to affect chronic HIV-1 infection in humanized mice. Following three, 100mg/kg FA-nanoATV/r intramuscular injections administered every other week to infected animals, viral RNA was at or below the detection limit, cell-associated HIV-1p24 reduced and CD4+ T cell counts protected. The dosing regimen improved treatment outcomes more than two fold from untargeted nanoATV/r. We posit that these nanoformulations have potential for translation to human use.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Portadores de Fármacos
/
Preparaciones de Acción Retardada
/
Antirretrovirales
/
Nanomedicina
/
Nanopartículas
/
Receptores de Folato Anclados a GPI
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Antiviral Res
Año:
2015
Tipo del documento:
Article
País de afiliación:
Estados Unidos